RALEIGH, N.C.--(BUSINESS WIRE)--LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care, today announced the start of the clinical development phase of a diagnostic test for cardiovascular disease based upon research demonstrating that a unique gut flora metabolite, trimethylamine-N-oxide (TMAO), is a predictor of cardiovascular risk.